Bari

• A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients … Ended recruitment
  2023-507130-24-00 5 2021-10-22 Neovascular age-related macular degeneration (nAMD)
• Adjuvant therapy in stage IV colorectal cancer patients NED Ended recruitment
  2024-518217-26-00 4 2021-10-20 Stage IV colorectal cancer patients with no evidence of disease (NED)
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa … Ended recruitment
  2023-503441-55-00 4 2021-10-14 Relapsed/Refractory Multiple Myeloma
• A trial to assess efficacy and safety of octreotide subcutaneous depot in patients with GEP-NET Ended recruitment
  2023-508723-12-00 5 2021-09-27 gastroenteropancreatic neuroendocrine tumors
• A trial for relapsed Multiple Myeloma patients (Isatuximab-dexamethasone) Ended recruitment
  2024-513397-21-00 4 2021-09-16 Relapsed Multiple Myeloma
• The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and … Ended recruitment
  2023-508968-30-00 5 2021-09-08 Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
• RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL.(REPRAB … Ended recruitment
  2024-518847-40-00 4 2021-07-16 recurrent ovarian cancer
• A Phase 3 Open Label, Randomized Study of LOXO 305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab … Ended recruitment
  2023-507697-40-00 5 2021-07-05 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• Optimizing MATRix, a combination of Methotrexate, Ara-C, Thiotepa and Rituximab given as an induction therapy, de-escalated in duration and … Ended recruitment
  2024-514473-21-00 5 2021-06-21 Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous s
• A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of … Ended recruitment
  2024-513227-16-00 5 2021-05-19 Immunoglobulin A Nephropathy (IgAN)
• An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First-line Treatment in Participants with Advanced … Ended recruitment
  2022-502122-41-00 5 2021-05-11 Clear cell renal cancer
• The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in pa … Ended recruitment
  2024-516868-28-00 4 2021-05-04 Ph+ Acute Lymphoblastic Leukemia
• A Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy Ended recruitment
  2023-506525-11-00 5 2021-04-19 Primary Membranous Nephropathy (pMN)
• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f … Ended recruitment
  2023-507961-24-00 5 2021-04-19 High-Risk HER2-Positive Breast Cancer
• Phase 3 Study of Belzutifan in Combination With Lenvatinib Versus Cabozantinib for Treatment of RCC Ended recruitment
  2024-510620-39-00 5 2021-04-19 Advanced RCC with clear cell component
• Early DOlutegravir/LAmivudine Switching after virological suppression (EDOLAS Study) Ended recruitment
  2024-518909-18-00 5 2021-03-23 HIV-1 infected individuals currently taking an INSTI-based three-drug
• MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucapar … Ended recruitment
  2024-516632-99-00 4 2021-03-17 Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian
• A Study of Osimertinib with or without Chemotherapy versus Chemotherapy alone as neoadjuvant therapy for Patients with Epidermal Growth Fact … Ended recruitment
  2022-502606-33-00 5 2021-02-26 Patients with histologically or cytologically documented non-squamous
• Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended recruitment
  2023-507263-19-00 5 2020-12-23 Advanced Non-Small Cell Lung Cancer
• Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Ended recruitment
  2023-503384-41-00 5 2020-12-22 Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
• Comparison of two strategies that use the same drugs but with inverted sequence for the treatment of patients with metastatic colorectal can … Ended recruitment
  2024-513296-41-00 4 2020-12-03 Colorectal cancer spread at distance, RAS BRAF wild type pretreatted
• A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL Ended recruitment
  2023-509358-72-00 5 2020-11-23 Diffuse large B-cell lymphoma
• A Clinical trial to compare the combination of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone versus the combination of Carfilzomib-Lenal … Ended recruitment
  2024-513422-38-00 5 2020-09-28 Newly diagnosed multiple myeloma
• POLAR BEAR Ended recruitment
  2022-502887-19-00 5 2020-08-18 Diffuse Large B-Cell Lymphoma

Showing 265–288 of 368 trials